These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35151649)

  • 1. Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.
    Kumari S; Sharma V; Tiwari R; Maurya JP; Subudhi BB; Senapati D
    Eur J Pharmacol; 2022 Mar; 919():174807. PubMed ID: 35151649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
    Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
    Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A; Dalla Volta A
    Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
    Davies AH; Beltran H; Zoubeidi A
    Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
    Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
    Shao C; Yu B; Liu Y
    Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
    Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
    Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM; Chi KN
    Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
    Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
    J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.